Trials / Completed
CompletedNCT06851221
Β3-adrenoreceptor As Prognostic Marker in Neuroblastoma and Ewing Sarcoma
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 95 (actual)
- Sponsor
- Meyer Children's Hospital IRCCS · Academic / Other
- Sex
- All
- Age
- 0 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
This study on biological samples of patients affected by neuroblastoma and Ewing sarcoma aims at validating the beta3-adrenoreceptor as prognostic biomarker.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | beta3 expression | the samples leftover from the standard diagnostic procedures will be analyzed for the expression of the beta3-adrenoreceptor |
Timeline
- Start date
- 2020-08-05
- Primary completion
- 2024-03-05
- Completion
- 2024-03-05
- First posted
- 2025-02-28
- Last updated
- 2025-02-28
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT06851221. Inclusion in this directory is not an endorsement.